These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 32370288

  • 21. Late onset multiple sclerosis: Is it really late onset?
    Roohani P, Emiru T, Carpenter A, Luzzio C, Freeman J, Scarberry S, Beaver G, Davidson L, Parry G.
    Mult Scler Relat Disord; 2014 Jul; 3(4):444-9. PubMed ID: 25877055
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Multiple Sclerosis Progression and Relapse Activity in Children.
    Iaffaldano P, Portaccio E, Lucisano G, Simone M, Manni A, Guerra T, Paolicelli D, Betti M, De Meo E, Pastò L, Razzolini L, Rocca MA, Ferrè L, Brescia Morra V, Patti F, Zaffaroni M, Gasperini C, De Luca G, Ferraro D, Granella F, Pozzilli C, Romano S, Gallo P, Bergamaschi R, Coniglio MG, Lus G, Vianello M, Banfi P, Lugaresi A, Totaro R, Spitaleri D, Cocco E, Di Palma F, Maimone D, Valentino P, Torri Clerici V, Protti A, Maniscalco GT, Salemi G, Pesci I, Aguglia U, Lepore V, Filippi M, Trojano M, Amato MP, Italian Multiple Sclerosis Register.
    JAMA Neurol; 2024 Jan 01; 81(1):50-58. PubMed ID: 38010712
    [Abstract] [Full Text] [Related]

  • 27. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
    Rzepiński Ł, Zawadka-Kunikowska M, Maciejek Z, Newton JL, Zalewski P.
    Medicina (Kaunas); 2019 May 31; 55(6):. PubMed ID: 31159275
    [Abstract] [Full Text] [Related]

  • 28. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
    D'Amico E, Patti F, Zanghì A, Chisari CG, Lo Fermo S, Zappia M.
    Eur J Neurol; 2018 Dec 31; 25(12):1425-1431. PubMed ID: 29956427
    [Abstract] [Full Text] [Related]

  • 29. Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics.
    Ghadiri F, Sahraian MA, Razazian N, Ashtari F, Poursadeghfard M, Nabavi SM, Navardi S, Baghbanian SM, Shaygannejad V, Harirchian MH, Beladimoghadam N, Majdinasab N, Hosseini S, Azimi A, Kamali H, Sharifipour E, Hosseini Nejad Mir N, Bayati A, Nahayati MA, Heidari H, Mozhdehipanah H, Ghalyanchi Langroodi H, Jalali N, Ayoubi S, Asadollahzadeh E, Ebadi Z, Eskandarieh S, Naser Moghadasi A.
    Mult Scler Relat Disord; 2023 Feb 31; 70():104493. PubMed ID: 36638768
    [Abstract] [Full Text] [Related]

  • 30. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 31; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 31. Late-onset multiple sclerosis in Isfahan, Iran.
    Etemadifar M, Abtahi SH, Minagar A, Akbari M, Masaeli A, Tabrizi N.
    Arch Iran Med; 2012 Oct 31; 15(10):596-8. PubMed ID: 23020533
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Late-onset MS is associated with an increased rate of reaching disability milestones.
    Andersen MA, Buron MD, Magyari M.
    J Neurol; 2021 Sep 31; 268(9):3352-3360. PubMed ID: 33677675
    [Abstract] [Full Text] [Related]

  • 34. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
    Hernandez L, O'Donnell M, Postma M, for MSOAC.
    Pharmacoeconomics; 2021 Feb 31; 39(2):243-256. PubMed ID: 32989685
    [Abstract] [Full Text] [Related]

  • 35. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A, Therapontos C, Horakova D, Szilasiová J, Kalniņa J, Kolontareva J, Gross-Paju K, Selmaj K, Sereike I, Milo R, Gabelić T, Rot U.
    Mult Scler Relat Disord; 2021 May 31; 50():102778. PubMed ID: 33592384
    [Abstract] [Full Text] [Related]

  • 36. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
    Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC.
    Brain; 2010 Jul 31; 133(Pt 7):1914-29. PubMed ID: 20534650
    [Abstract] [Full Text] [Related]

  • 37. Long-term disability progression of pediatric-onset multiple sclerosis.
    McKay KA, Hillert J, Manouchehrinia A.
    Neurology; 2019 Jun 11; 92(24):e2764-e2773. PubMed ID: 31092624
    [Abstract] [Full Text] [Related]

  • 38. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.
    Neurology; 2007 Oct 09; 69(15):1498-507. PubMed ID: 17699802
    [Abstract] [Full Text] [Related]

  • 39. Early predictors of conversion to secondary progressive multiple sclerosis.
    Barzegar M, Najdaghi S, Afshari-Safavi A, Nehzat N, Mirmosayyeb O, Shaygannejad V.
    Mult Scler Relat Disord; 2021 Sep 09; 54():103115. PubMed ID: 34216997
    [Abstract] [Full Text] [Related]

  • 40. Late onset multiple sclerosis.
    Arias M, Dapena D, Arias-Rivas S, Costa E, López A, Prieto JM, Corredera E.
    Neurologia; 2011 Jun 09; 26(5):291-6. PubMed ID: 21163234
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.